全国服务咨询热线:

Products产品中心
首页 > 产品中心 > 生化试剂 > 工具化合物 > abs810002SB 203580;152121-47-6

SB 203580;152121-47-6

简要描述:SB203580是一种p38 MAPK抑制剂,在THP-1细胞中IC50为0.3-0.5μM,对SAPK3(106T)和SAPK4(106T)选择性低10倍,且阻断PKB磷酸化,IC50为3-5μM。

  • 产品型号:abs810002
  • 厂商性质:生产厂家
  • 更新时间:2024-03-05
  • 访  问  量:1136

详细介绍

品牌absinCAS152121-47-6
分子式C21H16FN3OS纯度>98%
分子量377.44货号abs810002
规格5mg;10mg;100mg供货周期现货
主要用途-应用领域生物产业,综合

产品描述:

SB203580是一种p38 MAPK抑制剂,在THP-1细胞中IC50为0.3-0.5μM,对SAPK3(106T)和SAPK4(106T)选择性低10倍,且阻断PKB磷酸化,IC50为3-5μM。SB203580是第一个被报道的p38抑制剂。


保存方法:

Store at -20℃ for one year(Powder);Store at 2-4℃ for two weeks;Store at -20℃ for six months after dissolution.


别名:

Adezmapimod;RWJ 64809


外观:

white to off-white powder


可溶性/溶解性:

DMSO:43 mg/mL (113.92 mM)


靶点:

p38 MAPK;PKB


In vitro(体外研究):

SB203580 inhibits the IL-2-induced proliferation of primary human T cells, murine CT6 T cells, or BAF F7 B cells with an IC50 of 3–5 μm. SB203580 also inhibits IL-2-induced p70S6 kinase activation, although the concentration required is slightly higher with an IC50 above 10 μm. SB203580 also inhibits the activity of PDK1 in a dose-dependent manner with an IC50 in the 3–10 μm range. SB203580 inhibits p38-MAPK stimulation of MAPKAPK2 with an IC50 of approximately 0.07 μM, whereas inhibits total SAPK/JNK activity with an IC50 of 3–10 μM. SB203580 at higher concentrations activates the ERK pathway, which subsequently enhances NF-κB transcriptional activity. SB203580 induces autophagy in human hepatocellular carcinoma (HCC) cells.


In vivo(体内研究):

SB203580 protects pig myocardium against ischemic injury in an in vivo model. SB203580 is effective to prevent and treat the disease in MRL/lpr mice model of Systemic lupus erythematosus (SLE).


分子结构图:

 

产品咨询

留言框

  • 产品:

  • 您的单位:

  • 您的姓名:

  • 联系电话:

  • 常用邮箱:

  • 省份:

  • 详细地址:

  • 补充说明:

  • 验证码:

    请输入计算结果(填写阿拉伯数字),如:三加四=7
爱必信(上海)生物科技有限公司
地址:上海市浦东新区新浩路58号申江科创园18栋
邮箱:wulan@absin.cn
传真:
关注我们
欢迎您关注我们的微信公众号了解更多信息:
欢迎您关注我们的微信公众号
了解更多信息